Dolutegravir-Induced Acquired Sideroblastic Anemia in a HIV Positive Patient: A Challenging Hematologic Complication

KIRAN DHONJU1, Ashmita Gautam2, abhinav dahal1, Niraj Sharma3, Divas Adhikari4, Lina Devkota1, Prabhat Adhikari5, Sampurna Tuladhar5, Bishnu Pathak6, and Sabin Banmala6

1Sukraraj Tropical and Infectious Disease Hospital
2Tribhuvan University Institute of Medicine
3Tribhuvan University Teaching Hospital
4Bharatpur Hospital
5Civil Service Hospital
6Nepalese Army Institute of Health Sciences

August 16, 2023

Dolutegravir-Induced Acquired Sideroblastic Anemia in a HIV Positive Patient: A Challenging Hematologic Complication

Authors details:

1. Kiran Dhonju (Corresponding Author)Affiliation: Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal Contribution: Conceptualization, Data curation, Investigation, Methodology, Resources, Supervision, Writing- Original draft, Writing-review and editing Orcid: dhonjuk@gmail.com Email: dhonjuk@gmail.com

2. Ashmita GautamAffiliation: Tribhuvan University Institute of Medicine, Kathmandu, Nepal Contribution: Data curation, Investigation, Methodology, Project administration Resources, Writing- Original draft Email: dreamnachievea@gmail.com

3. Abhinav DahalAffiliation: Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal Contribution: Conceptualization, Data curation, Investigation, Resources, Supervision, Writing- Original draft, Writing-review and editing Email: abhinav.dahal333@gmail.cm

Niraj Kumar SharmaAffiliation: Tribhuvan University Institute of Medicine, Kathmandu, Nepal Contribution: Investigation, Resources, Supervision, Writing- review and editing Email: nirajkumarsharma97@gmail.com

Divas AdhikariAffiliation: Bharatpur Hospital, Bharatpur, Nepal Contribution: Supervision, Writing- original draft, Writing-review and editing Email: medivas13@gmail.com

Lina DevkotaAffiliation: Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal Contribution: Investigation, Resources, Writing- review and editing Email: adhoclina@gmail.com

Prabhat AdhikariAffiliation: Center for American Medical Specialists, Nepal Contribution: Supervision, Writing-review and editing
INTRODUCTION

Sideroblastic anemias (SAs) encompass a group of bone marrow disorders characterized by the abnormal accumulation of iron in the mitochondria of erythroid precursors. This leads to the formation of ring sideroblasts, where iron-laden mitochondria surround the nuclei of erythroblasts. Ring sideroblasts can be present in various pathological conditions, including both congenital and acquired forms of sideroblastic anemias. The underlying mechanisms leading to different forms of sideroblastic anemias are diverse. However, in all cases, the abnormal accumulation of iron is attributed to disruptions in mitochondrial proteins involved in regulating heme synthesis or Fe/S cluster synthesis. Additionally, impairment in translating mitochondrially encoded proteins contributes to this iron deposition. Consequently, these alterations give rise to ineffective erythropoiesis and iron accumulation in tissues, leading to tissue iron overload. It has been associated with antituberculin agents, chloramphenicol, and ethanol. While several etiological factors have been implicated in acquired sideroblastic anemia, including genetic mutations and exposure to toxins, the association between antiretroviral therapy and the development of Acquired sideroblastic anemia (ASA) is rare and has not been reported to date. Here we report the development of sideroblastic anemia in a patient who was on Dolutegravir therapy. Dolutegravir, an integrase strand transfer inhibitor (INSTI) exerts its antiviral activity by binding to the active site of HIV integrase preventing the stand transfer step crucial in the retroviral DNA integration process thus reducing viral load and slowing down disease progression. The association of ASA with Dolutegravir has not been established in the current literature. Naranjo method for estimating the probability of Adverse Drug Reaction (ADR) was used to show the casual association.

CASE PRESENTATION

A 35-year-old male from Boudha, Kathmandu, was diagnosed with HIV on 14th September 2016. As a result, his first Antiretroviral Therapy (ART) clinic visit occurred on 13th March 2017, and his CD4 count was measured at 500 cells/mm³. He started ART on 16th March 2017 with the Tenofovir Disoproxil Fumarate (TDF), Lamivudine (3TC), and Efavirenz (EFV) regimen.

During the initial days of treatment, he developed a rash as a side effect of Efavirenz (EFV). To manage the rash, Cortilone (corticosteroid) was prescribed for a week and the symptoms subsided. He underwent a complete blood count (CBC), renal function tests (RFT), and liver function tests (LFT) as part of his initial follow-up on March 29, 2017. The results showed a WBC count of 5400 cells/mm³, Hb of 14.30 g/dL, platelet count of 21800 cells/mm³, CD4 count of 525 cells/mm³, Creatinine (Cr) of 1.0 mg/dL, and ALT (SGPT) of 57 U/L.

Every six months, viral load testing was carried out, and the initial result on September 20, 2017, showed less than 20 copies, demonstrating effective viral suppression. He was started on Isoniazid Preventive Therapy on 24th August 2018 to prevent opportunistic tuberculosis infection. After six months of unremarkable therapy, it was discontinued.
EFV is known to be associated with neuropsychiatric symptoms like delirium, anxiety, acute psychosis, and an increased risk of suicidal thoughts. Following the national protocol guidelines, EFV was replaced with a similar drug from the same category i.e. Dolutegravir to avoid potential side effects on 10th June 2020.

After two months of continuing the TDF, 3TC, and DTG regimen, the patient came to OPD complaining of generalized fatiguability, dizziness, and headache for one week. Upon admission, the patient exhibited slight pallor without hepatosplenomegaly or lymphadenopathy. CBC revealed Hb 4.5 gm/dl, MCV of 68.6 fl, and MCH of 23.6 pg. PBS showed microcytic hypochromic red cells. Pencil cells were also seen. Any atypical cells/hemoparasites were not present. The stool for occult blood was negative. A blood transfusion was done and Hb was raised to 7.7gm/dl. Iron deficiency anemia was suspected and the patient was prescribed iron tablets. On follow-up after a week, the patient complained the symptoms did not subside. Hb was reduced to 3.6 gm/dl. Hematocrit was 9.9% and MCV of 80 fl. PBS revealed hypochromasia with anisopoikilocytosis with few polychromatophilic cells, smudge cells, and atypical white blood cells. LDH was 1600 U/L with total bilirubin and direct bilirubin of 2.7 mg/dl and 0.9 mg/dl respectively. The iron profile showed serum iron of 182 ug/dl, TIBC of 251 ug/dl, %Transferrin saturation of 72.5%, and serum ferritin of 1950 ng/ml. Antinuclear antibodies were 4.8 ODI (negative) and double-stranded DNA was 6.0 IU/ML (negative). The Direct Coombs test was negative. Hematological disorders and malignancies were not detected by chromosome analysis via karyotyping in bone marrow. Myelodysplastic syndrome with ring sideroblasts (>15%) was seen in bone marrow aspirate as shown in Figure 1. Mildly hypercellular marrow with erythroid hyperplasia was present in bone marrow biopsy as shown in Figure 2. The combination of these findings, along with the presence of marked myelofibrosis on bone marrow biopsy, led to a suspected diagnosis of idiopathic acquired sideroblastic anemia with a pre-leukemic state. According to Naranjo’s Adverse Drug Reaction (ADR) Assessment Scale, it received the “probable” level rating after scoring 6 points, as shown in Table 1.

As a result, Dolutegravir was replaced withRaltegravir and the new ART regimen was started.

Follow-up laboratory investigations conducted one month after discontinuing Dolutegravir is compared with those conducted before discontinuing the drug as shown in Table 2. The patient’s symptoms of fatigue and weakness also improved significantly. Subsequent monitoring over a period of six months demonstrated sustained hematologic recovery without the recurrence of anemia.

DISCUSSION:

With the features like high efficacy, good tolerability, a favorable safety profile, and the absence of significant drug-drug interaction, Integrase inhibitors are now recommended as the preferred first-line regimen for people living with HIV initiating antiretroviral therapy. They are a class of antiretroviral medications that act by blocking the integrase enzyme responsible for integrating double-stranded DNA into the host cell genome thus inhibiting HIV from multiplying and infecting other cells.

Dolutegravir, which was approved in 2013, is the most recent integrase inhibitor that is equally effective as or better than current treatment regimens in both treatment-experienced and treatment-naive individuals. Common adverse effects include headache, nausea, and diarrhea. With Dolutegravir, there is no increase in triglycerides, low-density lipoprotein, or total cholesterol that is seen with Protease inhibitors.

In our case, the patient developed the features of anemia like fatigue, generalized weakness, and shortness of breath after taking Dolutegravir (DTG) along with Tenofovir disoproxil fumarate (TDF) and Lamivudine (3TC) for three years. Initially, iron deficiency anemia was suspected and so baseline investigations along with iron profile were sent. But the serum ferritin level was high. Peripheral blood smear, Anti-nuclear antibody test, Direct Coomb’s test, and chromosomal analysis were also done. Considering the possibility of sideroblastic anemia, bone marrow aspirate and biopsy were planned. Sideroblastic anemias include a heterogeneous group of inherited/congenital and acquired disorders characterized by ineffective erythropoiesis and the presence of ring sideroblasts in the bone marrow aspirate. Ring sideroblasts, aberrant erythroblasts with iron-loaded mitochondria, are seen as a perinuclear ring of green-blue granules when stained with
Prussian blue. There should be a minimum of 5 granules encircling one-third of the nuclear diameter in this Prussian blue staining process known as the Perls reaction. Sideroblastic anemias can be grouped into inherited and acquired forms. The inherited forms are rare and characterized by three modes of inheritance: X-linked (XLSA), autosomal recessive (ARSA), or maternal. Acquired sideroblastic anemias can be classified into clonal (neoplastic) and nonclonal (nonneoplastic). Nonclonal, acquired sideroblastic anemias can be encountered in the setting of alcohol addiction and associated pyridoxine deficiency and are typically caused by dietary deficiencies or ingestion/accumulation of toxins. Alternative reasons include copper deficiency and medications including chloramphenicol, linezolid, penicillamine, busulfan, melphalan, and cycloserine (due to pyridoxine deficiency).

Although the prevalence of sideroblastic anemia has not been defined, it is rare. Regardless of the genetic variety and pathophysiologic variation among sideroblastic anemia subtypes, the diagnostic approach for sideroblastic anemia adheres to the same fundamental ideas. Before doing a clinical and genetic examination for congenital sideroblastic anemia, reversible causes of sideroblastic anemia and myelodysplastic syndrome must be ruled out. By definition, iron staining in the bone marrow aspirate is necessary for the diagnosis of all kinds of sideroblastic anemia. Excessive alcohol use, heavy metal toxicity, isoniazid, chloramphenicol, or linezolid treatment, malnutrition with following copper, vitamin B6, or thiamine deficiencies, as observed after bariatric surgery, are all reversible factors that should be carefully examined while eliciting a history. When reversible causes of sideroblastic anemia are considered, one must take into account atypical connections that patients might not be aware of. For example, prolonged high-zinc consumption from fad diets or routine use of zinc-containing denture treatments may not be evident causes of zinc poisoning and hemolytic anemia. This justifies including copper, ceruloplasmin, zinc, and lead levels in the diagnostic assessment even in situations when there isn’t a clear connection. In our patient, we ruled out these reversible causes by taking a detailed medical history, family history, personal history, and physical examination. During the first three years of continuing the Tenofovir Disoproxil Fumarate (TDF), Lamivudine (3TC), and Efavirenz (EFV) regimen, the patient never complained of symptoms of anemia like generalized fatigability, shortness of breath, weakness, etc. But after two months of introduction of Dolutegravir into the ART regimen, the symptoms of anemia started.

Whatever reversible cause might be causing sideroblastic anemia in this patient, removal of the offending agent is the first step of its management. In our case, the patient’s condition improved after stopping dolutegravir for a month. During a later six-month monitoring period, there was a sustained hematologic improvement without a recurrence of anemia. This discontinuation, along with the clinical presentation and bone marrow aspirate findings suggested dolutegravir as the reversible cause of acquired sideroblastic anemia.

CONCLUSION

To our knowledge, this is the first case report about Dolutegravir causing acquired sideroblastic anemia. Even though Dolutegravir is a new antiretroviral drug with effective virologic suppression, good tolerability, infrequent drug-drug interactions, and once-daily administration, patients might be experiencing certain side effects like sideroblastic anemia. Early recognition and prompt management of such issues is a must since it might impact drug compliance and ultimately the quality of life. The majority of individuals with anemia who are treated in primary care clinics are thought to have iron deficiency anemia, which is more frequent. Clinicians must, however, be aware of the potential for sideroblastic anemia. To properly manage the patient, the primary care physician, nurse practitioner, and internist must be able to identify and diagnose this illness. To assess the prognosis and epidemiology of this condition, more clinical research is also required.

ACKNOWLEDGEMENT

None.

FUNDING INFORMATION

None.
CONFLICT OF INTEREST
The authors report no conflicts of interest.

DATA AVAILABILITY STATEMENT
No data were used.

CONSENT STATEMENT
Written informed consent was obtained from the patient to publish this report in accordance with the journal’s patient consent policy.

REFERENCES


Hosted file

Hosted file